Traumatic brain injury biomarkers: From pipeline to diagnostic assay development

Methods in Molecular Biology

Volumn 566, Issue , 2009, Pages 293-302

  Oli, Monika W ^a   Hayes, Ronald L ^a   Robinson, Gillian ^a   Wang, Kevin K W ^b,c  

^a BANYAN BIOMARKERS INC   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c Banyan Biomakers Inc   (United States)

Author keywords

Assay development; Biomarkers; Brain injury; Clinical trials; ELISA

Indexed keywords

ANIMALIA;

BIOLOGICAL MARKER;

ANIMAL; ARTICLE; BIOASSAY; BRAIN INJURY; CLINICAL TRIAL; HUMAN; METABOLISM; METHODOLOGY; PROTEOMICS; REPRODUCIBILITY; SAFETY;

ANIMALS; BIOLOGICAL ASSAY; BIOLOGICAL MARKERS; BRAIN INJURIES; CLINICAL TRIALS AS TOPIC; DEVICE APPROVAL; HUMANS; PROTEOMICS; REPRODUCIBILITY OF RESULTS;

EID: 77449160866     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-59745-562-6_19     Document Type: Review

References (17)

1. Rifai N, Gillette MA, Carr SA (2006) Protein biomarker discovery and validation: The long and uncertain path to clinical utility. Nat Biotechnol 24, 971-983.
2. Vitzthum F, Behrens F, Anderson NL, Shaw JH (2005) Proteomics: From basic research to diagnostic application. A review of requirements and needs. J Proteome Res 4, 1086-1097.
3. Goldmann BU, Christenson RH, Hamm CW, Meinertz T, Ohman EM (2001) Implications of troponin testing in clinical medicine. Curr Control Trials Cardiovasc Med 2, 75-84.
4. Pike BR, Flint J, Johnson E, Glenn CC, Dutta S, Wang KKW Hayes RL (2001) Accumulation of calpain-cleaved non-erythroid aII-spectrin in cerebrospinal fluid after traumatic brain injury in rats. J Neurochem 78, 1297-1306.
5. Ringger NC, O'Steen BE, Brabham JG, Silver X, Pineda J, Wang KKW Hayes RL (2005) A novel marker for traumatic brain injury: CSF aII-spectrin breakdown product levels. J Neurotrauma 21, 1443-1456.
6. Pineda J, Liu MC, Aikman J, Akle V, Lewis S, Wang KKW, Robertson C, Hayes RL (2007) Clinical significance of aII-spectrin breakdown products in CSF after severe traumatic brain injury in human. J Neurotrauma 24, 354-366.
7. Kobeissy FH, Ottens AK, Zhang ZQ, Dave JR, Tortella FC, Hayes RL Wang KKW (2006) Differential proteomic analysis of traumatic brain injury biomarker study using CAX-PAGE/RPLC-MSMS method. Mol Cell Proteomics 5, 1887-1898.
8. Liu MC, Akle V, Zheng WR, Dave JR, Tortella FC, Hayes RL, Wang KKW (2006) Comparing calpain-and caspase-3-degradation patterns in traumatic brain injury by differential proteome analysis. Biochem J 394, 715-725.
9. Romeo MJ, Espina V, Lowenthal M, Espina BH, Petricoin EFI, Liotta LA (2005) CSF proteome: A protein repository for potential biomarker identification. Expert Rev Proteomics 2, 57-70.
10. Kobeissy FH, Larner SF, Sadasivan S, Zhiqun Zheng Z, Liu MC, Oli MW, Robinson G, Hayes RL, Wang KKW (2008) Neuroproteomic and systems biology-based discovery of protein biomarkers for traumatic brain injury and clinical validation (review). Proteomics Clin Appl 2, 1467-1483.
11. Anderson RE, Hansson LO, Nilsson O, Dijlai-Merzoug R, Settergren G (2001) High serum S100B levels for trauma patients without head injuries. Neurosurgery 48, 1255-1258.
12. Grebenchtchikov N, Sweep CG, Geurts-Moespot A, Piffanelli A, Foekens JA, Benraad TJ (2002) An ELISA avoiding interference by heterophilic antibodies in the measurement of components of the plasminogen activation system in blood. J Immunol Methods 268, 219-231.
13. Kricka LJ (1999) Human anti-animal antibody interferences in immunological assays. Clin Chem 45, 942-956.
14. Kricka LJ, Schmerfeld-Pruss D, Senior M, Goodman DB, Kaladas P (1990) Interference by human anti-mouse antibody in two-site immunoassays. Clin Chem 36, 892-894.
15. Niemeyer CM, Adler M, Wacker R (2005) Immuno-PCR: High sensitivity detection of proteins by nucleic acid amplification. Trends Biotechnol 23, 208-216.
16. Niemeyer CM, Adler M, Wacker R (2007) Detecting antigens by quantitative immuno-PCR. Nat Protocol 2, 1918-1930.
17. Katz R (2004) Biomarkers and surrogate markers: An FDA perspective. NeuroRx 1, 189-195.